Clinical trial
A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
NCT05166876 is registered in ClinicalTrials.gov with Clear Creek Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
- Lead sponsor
- Clear Creek Bio, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 1, 2022
- Completion date
- June 4, 2022
- Enrollment
- 26 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.